Genmab and Johnson & Johnson’s blockbuster cancer drug Darzalex is increasingly being used as a treatment for multiple myeloma according to a survey of oncologists conducted by Bloomberg Intelligence. 

The conclusion is that Darzalex is increasingly used as first and second-line treatment. In addition, Darzalex may be increasingly used as maintenance therapy, Bloomberg writes. 

In newly diagnosed patients who are eligible for stem cell transplantation, a new four-drug combination appears to be on its way to becoming standard of care. 

It is a treatment consisting of Darzalex, the cancer drugs Revlimid and Velcade, and the hormone drug Dexamethasone, according to Bloomberg Intelligence. 

According to Bloomberg Intelligence, the study shows that the treatment is already used in close to 40 percent of patients in the US and EU as first-line treatment. 

Darzalex is already a big seller for Genmab and its partner Johnson & Johnson. 

This year, Genmab expects Johnson & Johnson’s sales of Darzalex to reach USD 10.9-11.5 b, and Genmab expects unchanged royalty income from Darzalex sales of DKK 12.6-13.3b.